🚀 VC round data is live in beta, check it out!
Paul Hartmann Valuation Multiples
Discover revenue and EBITDA valuation multiples for Paul Hartmann and similar public comparables like Arjo, BioLife Solutions, Sopharma, Gerresheimer and more.
Paul Hartmann Overview
About Paul Hartmann
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
Founded
1818
HQ
Employees
11.0K
Website
Sectors
Financials (FY)
EV
$1B
Paul Hartmann Financials
Paul Hartmann reported last fiscal year revenue of $3B and EBITDA of $271M.
In the same fiscal year, Paul Hartmann generated $2B in gross profit, $271M in EBITDA, and $71M in net income.
Paul Hartmann P&L
In the most recent fiscal year, Paul Hartmann reported revenue of $3B and EBITDA of $271M.
Paul Hartmann expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA | — | XXX | $271M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Profit | — | XXX | $71M | XXX | XXX | XXX |
| Net Margin | — | XXX | 3% | XXX | XXX | XXX |
| Net Debt | — | — | $121M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Paul Hartmann Stock Performance
Paul Hartmann has current market cap of $883M, and enterprise value of $1B.
Market Cap Evolution
Paul Hartmann's stock price is $248.57.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $883M | -0.5% | XXX | XXX | XXX | $19.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPaul Hartmann Valuation Multiples
Paul Hartmann trades at 0.4x EV/Revenue multiple, and 3.8x EV/EBITDA.
Paul Hartmann Financial Valuation Multiples
As of March 28, 2026, Paul Hartmann has market cap of $883M and EV of $1B.
Equity research analysts estimate Paul Hartmann's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Paul Hartmann has a P/E ratio of 12.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $883M | XXX | $883M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 9.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.6x | XXX | XXX | XXX |
| P/E | — | XXX | 12.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 31.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Paul Hartmann Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Paul Hartmann Margins & Growth Rates
Paul Hartmann's revenue in the last fiscal year grew by 2%.
Paul Hartmann Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (6%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Paul Hartmann Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arjo | XXX | XXX | XXX | XXX | XXX | XXX |
| BioLife Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Gerresheimer | XXX | XXX | XXX | XXX | XXX | XXX |
| Salus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paul Hartmann M&A Activity
Paul Hartmann acquired XXX companies to date.
Last acquisition by Paul Hartmann was on XXXXXXXX, XXXXX. Paul Hartmann acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Paul Hartmann
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPaul Hartmann Investment Activity
Paul Hartmann invested in XXX companies to date.
Paul Hartmann made its latest investment on XXXXXXXX, XXXXX. Paul Hartmann invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Paul Hartmann
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Paul Hartmann
| When was Paul Hartmann founded? | Paul Hartmann was founded in 1818. |
| Where is Paul Hartmann headquartered? | Paul Hartmann is headquartered in Germany. |
| How many employees does Paul Hartmann have? | As of today, Paul Hartmann has over 11K employees. |
| Is Paul Hartmann publicly listed? | Yes, Paul Hartmann is a public company listed on Stuttgart Stock Exchange. |
| What is the stock symbol of Paul Hartmann? | Paul Hartmann trades under PHH2 ticker. |
| When did Paul Hartmann go public? | Paul Hartmann went public in 2016. |
| Who are competitors of Paul Hartmann? | Paul Hartmann main competitors are Arjo, BioLife Solutions, Sopharma, Gerresheimer. |
| What is the current market cap of Paul Hartmann? | Paul Hartmann's current market cap is $883M. |
| What is the current revenue of Paul Hartmann? | Paul Hartmann's last fiscal year revenue is $3B. |
| What is the current EV/Revenue multiple of Paul Hartmann? | Current revenue multiple of Paul Hartmann is 0.4x. |
| Is Paul Hartmann profitable? | No, Paul Hartmann is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.